A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)

Phase 3CompletedNCT00389896

Organon and Co150 enrolled

Overview

The purpose of this study is to see how well simvastatin raises HDL levels in patients with Type 2 Diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

150

Conditions

HDL Cholesterol

Interventions

MK0733 / Duration of Treatment: 18 WeeksDRUG

Comparator: placebo (unspecified) / Duration of Treatment: 18 WeeksDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient has stable Type 2 diabetes mellitus at Visit 1. * Patient meets screening criteria based on Visit 1 lab tests Exclusion Criteria: * Patient is pregnant, breastfeeding, or at risk of becoming pregnant * Patient has heart disease, uncontrolled high blood pressure, or other significant disease * Patient is taking prohibited medication(s) and is unable to stop taking them for the duration of the study

Outcomes

Primary Outcomes

HDL-C raising effects after 6 weeks

Time frame: 6 weeks

Secondary Outcomes

Effect on other lipids and lipoproteins at 6 weeks

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.